Skip to main content
Top
Published in: Current Rheumatology Reports 2/2012

01-04-2012 | CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Update on the Phenotypic Spectrum of Lesch-Nyhan Disease and its Attenuated Variants

Authors: Rosa J. Torres, Juan G. Puig, H. A. Jinnah

Published in: Current Rheumatology Reports | Issue 2/2012

Login to get access

Abstract

Congenital deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT) results in a spectrum of clinical phenotypes. All of these phenotypes are associated with marked overproduction of uric acid and related problems such as hyperuricemia, urate nephrolithiasis, tophi, and gout. The mildest phenotypes include only problems related to overproduction of uric acid. The most severe phenotype is known as Lesch-Nyhan disease, in which the phenotype also includes severe motor handicap, intellectual disability, and self-injurious behavior. In between these two extremes is a continuous spectrum of phenotypes with varying degrees of motor and cognitive handicap but no self-injurious behavior. The pathogenesis of overproduction of uric acid in HPRT deficiency is well-understood, and treatments are available to control it. The pathogenesis of the neurobehavioral problems is less well-understood, and effective treatments for them are lacking.
Literature
1.
go back to reference Torres RJ, Puig JG. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis. 2007;2:48.PubMedCrossRef Torres RJ, Puig JG. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis. 2007;2:48.PubMedCrossRef
2.
go back to reference Jinnah HA, Friedmann T. Lesch-Nyhan disease and its variants. In: Scriver CR et al., editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 2537–70. Jinnah HA, Friedmann T. Lesch-Nyhan disease and its variants. In: Scriver CR et al., editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 2537–70.
3.
go back to reference Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med. 1964;36:561–70.PubMedCrossRef Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med. 1964;36:561–70.PubMedCrossRef
4.
go back to reference Visser JE, Baer PR, Jinnah HA. Lesch-Nyhan syndrome and the basal ganglia. Brain Res Rev. 2000;32:449–75.PubMedCrossRef Visser JE, Baer PR, Jinnah HA. Lesch-Nyhan syndrome and the basal ganglia. Brain Res Rev. 2000;32:449–75.PubMedCrossRef
5.
go back to reference Jinnah HA, et al. Delineation of the motor disorder of Lesch-Nyhan disease. Brain. 2006;129:1201–17.PubMedCrossRef Jinnah HA, et al. Delineation of the motor disorder of Lesch-Nyhan disease. Brain. 2006;129:1201–17.PubMedCrossRef
6.
go back to reference Schretlen DS, et al. Neurocognitive functioning in Lesch-Nyhan disease and partial hypoxanthine-guanine phosphoribosyltransferase deficiency. J Int Neuropsychol Soc. 2001;7:805–12.PubMedCrossRef Schretlen DS, et al. Neurocognitive functioning in Lesch-Nyhan disease and partial hypoxanthine-guanine phosphoribosyltransferase deficiency. J Int Neuropsychol Soc. 2001;7:805–12.PubMedCrossRef
7.
8.
go back to reference Sweetman L, Nyhan WL. Excretion of hypoxanthine and xanthine in a genetic disease of purine metabolism. Nature. 1967;215:859–60.PubMedCrossRef Sweetman L, Nyhan WL. Excretion of hypoxanthine and xanthine in a genetic disease of purine metabolism. Nature. 1967;215:859–60.PubMedCrossRef
9.
go back to reference Kaufman JM, Greene ML, Seegmiller JE. Urine uric acid to creatinine ratio—a screening test for inherited disorders of purine metabolism. J Pediatr. 1968;73:583–92.PubMedCrossRef Kaufman JM, Greene ML, Seegmiller JE. Urine uric acid to creatinine ratio—a screening test for inherited disorders of purine metabolism. J Pediatr. 1968;73:583–92.PubMedCrossRef
10.
go back to reference •• Jinnah HA, et al. Attenuated variants of Lesch-Nyhan disease. Brain. 2010;133: 671–89. This is the largest and most comprehensive summary of LND variants published to date, with detailed information on the clinical phenotype and genetics. It questions the value of dividing the phenotype into two or three distinct patient subgroups and instead argues for a continuum of disease severity. PubMedCrossRef •• Jinnah HA, et al. Attenuated variants of Lesch-Nyhan disease. Brain. 2010;133: 671–89. This is the largest and most comprehensive summary of LND variants published to date, with detailed information on the clinical phenotype and genetics. It questions the value of dividing the phenotype into two or three distinct patient subgroups and instead argues for a continuum of disease severity. PubMedCrossRef
11.
go back to reference Puig JG, et al. The spectrum of hypoxanthine-guanine phosphoribosyltransferase deficiency: clinical experience based on 22 patients from 18 Spanish families. Medicine. 2001;80:102–12.PubMedCrossRef Puig JG, et al. The spectrum of hypoxanthine-guanine phosphoribosyltransferase deficiency: clinical experience based on 22 patients from 18 Spanish families. Medicine. 2001;80:102–12.PubMedCrossRef
12.
go back to reference Emmerson BT, Thompson L. The spectrum of hypoxanthine-guanine phosphoribosyltranferase deficiency. Q J Med. 1973;166:423–40. Emmerson BT, Thompson L. The spectrum of hypoxanthine-guanine phosphoribosyltranferase deficiency. Q J Med. 1973;166:423–40.
13.
go back to reference Kelley WN, et al. Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout. Ann Int Med. 1969;70:155–206.PubMed Kelley WN, et al. Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout. Ann Int Med. 1969;70:155–206.PubMed
14.
go back to reference Catel W, Schmidt J. Uber familiare gichtische Diathese in Verbindung mit zerebralen und renalen Symptomen bei einem Kleinkind. Dtsch Med Wschr. 1959;84:2145–7.PubMedCrossRef Catel W, Schmidt J. Uber familiare gichtische Diathese in Verbindung mit zerebralen und renalen Symptomen bei einem Kleinkind. Dtsch Med Wschr. 1959;84:2145–7.PubMedCrossRef
15.
go back to reference Bakay B, et al. Utilization of purines by an HPRT variant in an intelligent, nonmutilative patient with features of the Lesch-Nyhan syndrome. Pediatr Res. 1979;13:1365–70.PubMedCrossRef Bakay B, et al. Utilization of purines by an HPRT variant in an intelligent, nonmutilative patient with features of the Lesch-Nyhan syndrome. Pediatr Res. 1979;13:1365–70.PubMedCrossRef
16.
go back to reference Bakay B, et al. Variation in human HPRT and its relationship to neurologic and behavioral manifestations. Adv Exp Med Biol. 1980;122A:317–25.PubMed Bakay B, et al. Variation in human HPRT and its relationship to neurologic and behavioral manifestations. Adv Exp Med Biol. 1980;122A:317–25.PubMed
17.
go back to reference Marie J, Royer P, Rappaport R. Hyperuricemie congenitale avec troubles neurologiques, renaux et sanguins. Arch Fr Pediatr. 1967;24:501–10.PubMed Marie J, Royer P, Rappaport R. Hyperuricemie congenitale avec troubles neurologiques, renaux et sanguins. Arch Fr Pediatr. 1967;24:501–10.PubMed
18.
go back to reference Van Bogaert L, Van Damme J, Verschueren M. On a progressive syndrome of extrapyramidal hypertonia with gouty osteoarthropathies in 2 brothers. Rev Neurol (Paris). 1966;114:15–32. Van Bogaert L, Van Damme J, Verschueren M. On a progressive syndrome of extrapyramidal hypertonia with gouty osteoarthropathies in 2 brothers. Rev Neurol (Paris). 1966;114:15–32.
19.
go back to reference Laplane R, Polonovski C, Graveleau D. Congenital hyperuricemia in a cerebro-renal form. Arch Fr Pediatr. 1967;24:103–4.PubMed Laplane R, Polonovski C, Graveleau D. Congenital hyperuricemia in a cerebro-renal form. Arch Fr Pediatr. 1967;24:103–4.PubMed
20.
go back to reference Polonovski C, et al. Encephalopathie et nephropathie metaboliques par hyperuricemie congenitale. Bull Mem Soc Med Hop Paris. 1966;117:799–812.PubMed Polonovski C, et al. Encephalopathie et nephropathie metaboliques par hyperuricemie congenitale. Bull Mem Soc Med Hop Paris. 1966;117:799–812.PubMed
21.
go back to reference Nyhan WL. Ataxia and disorders of purine metabolism: defects in hypoxanthine guanine phosphoribosyl transferase and clinical ataxia. Adv Neurol. 1978;21:279–87.PubMed Nyhan WL. Ataxia and disorders of purine metabolism: defects in hypoxanthine guanine phosphoribosyl transferase and clinical ataxia. Adv Neurol. 1978;21:279–87.PubMed
22.
go back to reference Jinnah HA, et al. The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res. 2000;463:309–26.PubMedCrossRef Jinnah HA, et al. The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res. 2000;463:309–26.PubMedCrossRef
23.
go back to reference Jinnah HA, et al. The spectrum of mutations causing HPRT deficiency: an update. Nucleos Nucleot Nucleic Acids. 2004;23:1153–60.CrossRef Jinnah HA, et al. The spectrum of mutations causing HPRT deficiency: an update. Nucleos Nucleot Nucleic Acids. 2004;23:1153–60.CrossRef
24.
go back to reference Becker MA. Hyperuricemia and gout. In: Scriver CR et al., editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill Book Company; 2001. p. 2513–35. Becker MA. Hyperuricemia and gout. In: Scriver CR et al., editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill Book Company; 2001. p. 2513–35.
25.
26.
go back to reference Seegmiller JE. Contributions of Lesch-Nyhan syndrome to the understanding of purine metabolism. J Inherit Metab Dis. 1989;12:184–96.PubMedCrossRef Seegmiller JE. Contributions of Lesch-Nyhan syndrome to the understanding of purine metabolism. J Inherit Metab Dis. 1989;12:184–96.PubMedCrossRef
27.
go back to reference Rosenbloom FM, et al. Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem. 1968;243:1166–73.PubMed Rosenbloom FM, et al. Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem. 1968;243:1166–73.PubMed
28.
go back to reference Brosh S, et al. De novo synthesis of purine nucleotides in human peripheral blood leukocytes. J Clin Invest. 1976;58:289–97.PubMedCrossRef Brosh S, et al. De novo synthesis of purine nucleotides in human peripheral blood leukocytes. J Clin Invest. 1976;58:289–97.PubMedCrossRef
29.
go back to reference Sorensen LB. Mechanism of excessive purine biosynthesis in hypoxanthine-guanine phosphoribosyltransferase deficiency. J Clin Invest. 1970;49:968–78.PubMedCrossRef Sorensen LB. Mechanism of excessive purine biosynthesis in hypoxanthine-guanine phosphoribosyltransferase deficiency. J Clin Invest. 1970;49:968–78.PubMedCrossRef
31.
go back to reference Martinon F, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–41.PubMedCrossRef Martinon F, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–41.PubMedCrossRef
32.
go back to reference Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep. 2011;13:160–6.PubMedCrossRef Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep. 2011;13:160–6.PubMedCrossRef
33.
go back to reference Torres RJ, Prior C, Puig JG. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. Metabolism. 2007;56:1179–86.PubMedCrossRef Torres RJ, Prior C, Puig JG. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. Metabolism. 2007;56:1179–86.PubMedCrossRef
34.
go back to reference Klinenberg JR, Goldfinger SE, Seegmiller JE. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med. 1965;62:639–47.PubMed Klinenberg JR, Goldfinger SE, Seegmiller JE. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med. 1965;62:639–47.PubMed
36.
go back to reference Sikora P, et al. Acute renal failure due to bilateral xanthine urolithiasis in a boy with Lesch-Nyhan syndrome. Pediatr Nephrol. 2006;21:1045–7.PubMedCrossRef Sikora P, et al. Acute renal failure due to bilateral xanthine urolithiasis in a boy with Lesch-Nyhan syndrome. Pediatr Nephrol. 2006;21:1045–7.PubMedCrossRef
37.
go back to reference • Oh MM, et al. Urine alkalinization may be enough for the treatment of bilateral renal pelvis stones associated with Lesch-Nyhan syndrome. Urol Res. 2011;39:417–9. This article describes a simple and noninvasive method of dissolving uric acid stones in LND. PubMedCrossRef • Oh MM, et al. Urine alkalinization may be enough for the treatment of bilateral renal pelvis stones associated with Lesch-Nyhan syndrome. Urol Res. 2011;39:417–9. This article describes a simple and noninvasive method of dissolving uric acid stones in LND. PubMedCrossRef
38.
go back to reference Oka T, et al. Xanthine calculi in the patient with the Lesch-Nyhan syndrome associated with urinary tract infection. Urol Int. 1985;40:138–40.PubMedCrossRef Oka T, et al. Xanthine calculi in the patient with the Lesch-Nyhan syndrome associated with urinary tract infection. Urol Int. 1985;40:138–40.PubMedCrossRef
39.
go back to reference Becker MA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–61.PubMedCrossRef Becker MA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–61.PubMedCrossRef
40.
go back to reference • Roche A, et al. Efficacy of rasburicase in hyperuricemia secondary to Lesch-Nyhan syndrome. Am J Kidney Dis. 2009;53:677–80. This study describes the potential use of a novel therapy for particularly difficult patients with LND who have developed renal failure as a result of nephrolithiasis. PubMedCrossRef • Roche A, et al. Efficacy of rasburicase in hyperuricemia secondary to Lesch-Nyhan syndrome. Am J Kidney Dis. 2009;53:677–80. This study describes the potential use of a novel therapy for particularly difficult patients with LND who have developed renal failure as a result of nephrolithiasis. PubMedCrossRef
Metadata
Title
Update on the Phenotypic Spectrum of Lesch-Nyhan Disease and its Attenuated Variants
Authors
Rosa J. Torres
Juan G. Puig
H. A. Jinnah
Publication date
01-04-2012
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 2/2012
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-011-0231-5

Other articles of this Issue 2/2012

Current Rheumatology Reports 2/2012 Go to the issue

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

The Patient’s Experience of Gout: New Insights to Optimize Management

PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

Granulomatosis with Polyangiitis in Childhood

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Regulation of Uric Acid Excretion by the Kidney

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.